Macrophages are thought to represent one of the first cell types in the body to be infected
during the early stage of human immunodeficiency virus type 1 (HIV-1) transmission and …

Debio‐025 is an oral cyclophilin (Cyp) inhibitor with potent anti–hepatitis C virus activity in
vitro. Its effect on viral load as well as its influence on intracellular Cyp levels was investigated …

… to 2.5 μm. Debio 025 (gift from Debiopharm, Lausanne, Switzerland) was prepared in
ethanol at 10 mm and diluted further in tissue culture medium to 2 μm for each experiment. …

This study demonstrates that syndecan functions as an in trans HIV receptor. We show that
syndecan, when expressed in nonpermissive cells, becomes the major mediator for HIV …

Although the transport of human immunodeficiency virus type 1 (HIV-1) through the epithelium
is critical for HIV-1 colonization, the mechanisms controlling this process remain obscure. …

DEB025/Debio 025 (Alisporivir) is a cyclophilin (Cyp)-binding molecule with potent anti-hepatitis
C virus (HCV) activity both in vitro and in vivo. It is currently being evaluated in phase II …

Dendritic cells (DCs) efficiently capture HIV-1 and mediate transmission to T cells, but the
underlying molecular mechanism is still being debated. The C-type lectin DC-SIGN is …

Debio-025 is a synthetic cyclosporine with no immunosuppressive capacity but a high
inhibitory potency against cyclophilin A (CypA)-associated cis-trans prolyl isomerase (PPIase) …

… We deeply thank M. Witte and M. Weinand for providing primary BMECs from discarded
temporal lobe tissues. We thank M. Emerman for providing us with the Jurkat-CCR5 cells and P. …

The present study proposes a novel mode of action for cyclophilin A (CypA) in the HIV-1 life
cycle. We demonstrate that CypA-deficient viruses do not replicate because they fail to …